
Janssen Defends Remicade Patents in New Lawsuit
Janssen filed a lawsuit in a US District Court in New Jersey against Samsung Bioepis, claiming the company’s new biosimilar infringed on its Remicade patents.
On May 17, 2017, Janssen, a subsidiary of Johnson & Johnson (J&J), filed a lawsuit in a district court in New Jersey against Samsung Bioepis, alleging the company’s
Renflexis is the second FDA-approved biosimilar for Remicade and the first Samsung Bioepis product approved for marketing in the US. Samsung
"We are confident we do not infringe Janssen's patents," Samsung Bioepis told Reuters. "We will take all necessary measures against Janssen's attempts to violate patient rights and deny patient access to effective, lower-cost treatment options."
Remicade is a blockbuster treatment for J&J and accounted for approximately 9.7% of the company’s 2016 revenue.
Source: United States District Court of New Jersey, Reuters
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.